London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from ...

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH ...

Investigational efimosfermin alfa was safe and well tolerated among patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH), a randomized phase IIa trial showed. Among 65 ...

Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.

GSK also expects a regulatory decision on depemokimab in December and further pipeline entries such as efimosfermin. Despite the re-rating, GSK shares continue to trade at a discount. Specifically, it ...

Developed by Boston Pharmaceuticals, efimosfermin is a fibroblast growth factor 21 (FGF21) analog currently in midstage clinical trials for steatotic liver disease, including metabolic dysfunction ...

Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD).

Efimosfermin, with its direct antifibrotic mechanism of action, has the potential to establish a new standard of care for treating MASH.

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa ...